| Drug Name: | verapamil (52-53-9) |
|---|---|
| PubChem ID: | 2520 |
| SMILES: | CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC |
| InchiKey: | SGTNSNPWRIOYBX-UHFFFAOYSA-N |
| Therapeutic Category: | Anti-Arrhythmia Agents, Calcium Channel Blockers, Cardiovascular Agents, Membrane Transport Modulators, Vasodilator Agents |
| Molecular Weight (dalton) | : | 454.611 |
| LogP | : | 5.09308 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 6 |
| Hydrogen Bond Donor Count | : | 0 |
| Total Polar Surface Area | : | 63.95 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Disopyramide ((3737-09-5)) | Hypotension | Additive | Not established | Collapse after oral administration of disopyramide |
| Dofetilide (115256-11-6) | Torsade De Pointes | Synergistic | Verapamil is postulated to interact with dofetilide by increasing its rate of absorption by increasing hepatic blood flow. There is a linear relationship between plasma dofetilide concentrations and prolongation of the QT interval, which is a risk factor for torsade de pointes | Transient kinetic and dynamic interactions between verapamil and dofetilide, a class III antiarrhythmic |
| Almotriptan (154323-57-6) | Blood Pressure Systolic Increased | Synergistic | verapamil may inhibit the metabolism of almotriptan via the cytochrome P450 isoenzyme CYP3A4 | Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers |
| Carbamazepine (298-46-4) | Carbamazepine Toxicity | Synergistic | verapamil inhibit the metabolism of carbamazepine by the cytochrome P450 isoenzyme CYP3A4, thereby reducing its loss from the body and increasing serum levels | Verapamil-carbamazepine neurotoxicity |
| Flecainide (54143-55-4) | Asystole | Additive | Flecainide and verapamil have little or no effects on the pharmacokinetics of each other, but they can apparently have additive depressant effects on the heart | Asystole and cardiogenic shock due to combined treatment with verapamil and flecainide |
| Quinidine (56-54-2) | Hypotension | Antagonistic | The interaction with verapamil is probably due to an inhibitory effect of verapamil on the metabolism of quinidine (inhibition of cytochrome P450 isoenzyme CYP3A). The marked hypotension observed may be related to the antagonistic effects of the two drugs on catecholamine-induced alpha-receptor induced vasoconstriction | The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine |
| Epirubicin (56420-45-2) | Bone Marrow Depression | Antagonistic | Not known | Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil |
This panel provides drug-protein interaction and their ADRs along with references
This panel provides drug-food interactions and their ADRs along with references
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category